ATE445016T1 - Verwendung von fkbp-chaperons als expressionswerkzeug - Google Patents

Verwendung von fkbp-chaperons als expressionswerkzeug

Info

Publication number
ATE445016T1
ATE445016T1 AT02747428T AT02747428T ATE445016T1 AT E445016 T1 ATE445016 T1 AT E445016T1 AT 02747428 T AT02747428 T AT 02747428T AT 02747428 T AT02747428 T AT 02747428T AT E445016 T1 ATE445016 T1 AT E445016T1
Authority
AT
Austria
Prior art keywords
hiv
chaperone
variant
chaperons
fkbp
Prior art date
Application number
AT02747428T
Other languages
English (en)
Inventor
Christian Scholz
Herbert Andres
Elke Faatz
Alfred Engel
Urban Schmitt
Ariuna Bazarsuren
Peter Schaarschmidt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE445016T1 publication Critical patent/ATE445016T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
AT02747428T 2001-06-22 2002-06-24 Verwendung von fkbp-chaperons als expressionswerkzeug ATE445016T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01115225 2001-06-22
EP01120939 2001-08-31
PCT/EP2002/006957 WO2003000878A2 (en) 2001-06-22 2002-06-24 Use of fkbp chaperones as expression tool

Publications (1)

Publication Number Publication Date
ATE445016T1 true ATE445016T1 (de) 2009-10-15

Family

ID=26076626

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02758265T ATE522603T1 (de) 2001-06-22 2002-06-24 Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
AT02747428T ATE445016T1 (de) 2001-06-22 2002-06-24 Verwendung von fkbp-chaperons als expressionswerkzeug

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02758265T ATE522603T1 (de) 2001-06-22 2002-06-24 Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält

Country Status (16)

Country Link
US (2) US7244819B2 (de)
EP (3) EP1402041B1 (de)
JP (6) JP4262594B2 (de)
KR (2) KR100611545B1 (de)
CN (1) CN100510068C (de)
AT (2) ATE522603T1 (de)
AU (2) AU2002317841A1 (de)
BR (1) BRPI0210598B8 (de)
CA (3) CA2449747C (de)
DE (1) DE60233942D1 (de)
DK (2) DK1402015T3 (de)
ES (3) ES2333108T3 (de)
HK (1) HK1068918A1 (de)
MX (1) MXPA03011455A (de)
PL (2) PL218245B1 (de)
WO (2) WO2003000877A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1402015T3 (da) * 2001-06-22 2011-12-05 Hoffmann La Roche Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
EP1516928B1 (de) * 2002-06-25 2010-02-17 Sekisui Chemical Co., Ltd. Expressionsvektor, wirt, fusionsprotein, verfahren zur herstellung von fusionsprotein und verfahren zur herstellung von protein
AU2003283205A1 (en) * 2002-11-26 2004-06-18 Danmarks Fodevare- Og Veterinaerforskning Dendrimer conjugates for selective of protein aggregates
EP1621555A4 (de) * 2003-04-18 2006-08-02 Sekisui Chemical Co Ltd Immunogen, zusammensetzung zur immunologischen verwendung und verfahren zur herstellung von antikörpern unter deren verwendung
US9057061B2 (en) * 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
US7604935B2 (en) 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
WO2007077008A1 (en) 2006-01-03 2007-07-12 Roche Diagnostics Gmbh Chimaeric fusion protein with superior chaperone and folding activities
WO2007141650A2 (en) * 2006-01-17 2007-12-13 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection
US8962262B2 (en) 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
ATE529436T1 (de) 2007-04-20 2011-11-15 Hoffmann La Roche Erkennung von primären infektionen mit krankheitserregern
WO2009031852A2 (en) * 2007-09-06 2009-03-12 Korea University Industry and Academy Cooperation Foundation Preparation method of recombinant protein by use of a fusion expression partner
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
ES2450998T3 (es) 2007-12-13 2014-03-26 F. Hoffmann-La Roche Ag Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola
EP2127678A1 (de) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA als Werkzeug für recombinante Protein-und Enzym-technologie
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
CA2826142A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2617731A1 (de) 2012-01-19 2013-07-24 Roche Diagnostics GmbH Lösliche immunreaktive Treponem pallidum TpN47 Antigene
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2706115A1 (de) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperon-Chaperon-Fusionspolypeptide zur Reduzierung der Störungen und Stabilisierung von Immunoassays
US9725511B2 (en) * 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
ES2603589T3 (es) * 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
EP2827146A1 (de) 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae Lipoprotein 15 (Lp15)-Varianten als entstörende Zusätze bei TPN17-basierten Immunoassays zum Nachweis von Anti-Treponema-Antikörpern
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP2913338A1 (de) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Lösliche und immunoreaktive Varianten von HTLV-Antigen-Kapsid P24
JP2015215244A (ja) * 2014-05-12 2015-12-03 富士レビオ株式会社 免疫測定における抗ｈｔｌｖ抗体の検出感度を向上させる方法
BR112016024457A2 (pt) 2014-05-14 2018-01-23 Hoffmann La Roche anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
MX2016014862A (es) * 2014-05-14 2017-02-27 Hoffmann La Roche Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
BR112017011662A2 (pt) 2014-12-01 2018-02-27 Pfenex Inc parceiros de fusão para a produção de peptídeo
US20180023098A1 (en) * 2015-02-13 2018-01-25 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
JP7044721B2 (ja) 2016-05-31 2022-03-30 エフ．ホフマン－ラ ロシュ アーゲー Ｈｃｖコア抗原の迅速な検出のための前処理法
KR102165623B1 (ko) 2016-05-31 2020-10-15 에프. 호프만-라 로슈 아게 바이러스 항원의 혈청학적 탐지 방법
EP3472322B1 (de) * 2016-06-20 2022-01-05 MetGen Oy Verfahren zur gewinnung von aktiver unlöslicher xylose-isomerase
ES2865511T3 (es) 2017-02-02 2021-10-15 Hoffmann La Roche Inmunoanálisis que usa al menos dos agentes de unión específica a analito pegilado
CN110709410A (zh) 2017-04-26 2020-01-17 豪夫迈·罗氏有限公司 可溶性和免疫反应性寨卡病毒ns1多肽
BR112019027491A2 (pt) 2017-07-27 2020-07-07 F. Hoffmann-La Roche Ag proteína de fusão multiepítopo, método de produção de uma proteína, uso de uma proteína, método para detectar o antígeno e kit
CN110066343B (zh) * 2019-05-23 2021-04-09 北京新创生物工程有限公司 一种用于检测hiv新发感染的重组抗原及其应用
WO2021214248A1 (en) 2020-04-23 2021-10-28 F. Hoffmann-La Roche Ag Corona nucleocapsid antigen for use in antibody-immunoassays
WO2023012321A1 (en) 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
WO2023213758A1 (en) 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Hiv gp41 variants for immunodiagnostic assays

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4735896A (en) 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
DE3705686C2 (de) 1987-02-23 1995-11-30 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Antikörpern
NZ224663A (en) 1987-05-28 1990-11-27 Amrad Corp Ltd Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors
SE8704185L (sv) 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
AU667669B2 (en) 1991-06-14 1996-04-04 Idexx Laboratories, Inc. Detection of mammalian immunodeficiency viruses
JPH07504561A (ja) * 1991-12-20 1995-05-25 ノボ　ノルディスク　アクティーゼルスカブ リパーゼの製造のための方法
JP2001504572A (ja) 1992-04-09 2001-04-03 アボツト・ラボラトリーズ Ｈｉｖ抗原及びｈｉｖ抗体を検出するためのアッセイ
AU4400593A (en) 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
EP0663010B1 (de) 1992-10-02 2000-08-09 Research Corporation Technologies, Inc. Methoden der erhöhung der sekretion von überexpremierten proteinen
US5459051A (en) 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
AU3968595A (en) 1994-10-25 1996-05-15 Board Of Trustees Of The Leland Stanford Junior University Conditional transformation of genetically engineered cells
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
EP0855029A4 (de) 1995-09-15 2000-03-08 Merck & Co Inc Ein assay mit hohern durchsatz unter verwendung von fusionsprotein
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9614114D0 (en) 1996-07-05 1996-09-04 Amcor Packaging Uk Ltd New packages
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
US6225082B1 (en) 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
US5989868A (en) * 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
DE19913117A1 (de) * 1998-05-06 1999-11-11 Roche Diagnostics Gmbh Entstörung durch Rheumafaktoren
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
ATE473755T1 (de) * 1998-10-02 2010-07-15 Rhein Biotech Proz & Prod Gmbh Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus
WO2000028011A2 (en) 1998-11-06 2000-05-18 President And Fellows Of Harvard College Fk506-based regulation of biological events
WO2000055183A1 (en) 1999-03-17 2000-09-21 Medical Research Council Method for refolding molecules of polypeptides containing ig domains
EP1189934A2 (de) 1999-05-14 2002-03-27 Medical Research Council Oligomere chaperonproteine
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
CA2403718A1 (en) 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
JP2002262883A (ja) * 2001-03-13 2002-09-17 Sekisui Chem Co Ltd モノクローナル抗体の製造方法
DK1402015T3 (da) * 2001-06-22 2011-12-05 Hoffmann La Roche Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD

Also Published As

Publication number Publication date
CN100510068C (zh) 2009-07-08
ATE522603T1 (de) 2011-09-15
JP4309910B2 (ja) 2009-08-05
ES2333108T3 (es) 2010-02-17
ES2372031T3 (es) 2012-01-13
JP4320351B2 (ja) 2009-08-26
DE60233942D1 (de) 2009-11-19
JP2009100770A (ja) 2009-05-14
WO2003000877A2 (en) 2003-01-03
WO2003000878A3 (en) 2003-10-09
EP1402041A2 (de) 2004-03-31
DK2267452T3 (da) 2012-10-29
CA2770453A1 (en) 2003-01-03
AU2002317841A1 (en) 2003-01-08
CA2450476C (en) 2012-05-15
KR100702373B1 (ko) 2007-04-02
EP1402015B1 (de) 2011-08-31
DK1402015T3 (da) 2011-12-05
PL367679A1 (en) 2005-03-07
BRPI0210598B8 (pt) 2021-05-25
JP4523660B2 (ja) 2010-08-11
BR0210598A (pt) 2004-07-20
PL397776A1 (pl) 2012-07-16
JP2007125026A (ja) 2007-05-24
US20030096352A1 (en) 2003-05-22
EP2267452B8 (de) 2012-11-14
CA2450476A1 (en) 2003-01-03
CA2449747A1 (en) 2003-01-03
US20090028893A1 (en) 2009-01-29
JP2009102320A (ja) 2009-05-14
CA2770453C (en) 2014-12-09
JP4174422B2 (ja) 2008-10-29
BRPI0210598B1 (pt) 2018-11-13
US7244819B2 (en) 2007-07-17
KR20040010774A (ko) 2004-01-31
JP2004534831A (ja) 2004-11-18
EP2267452B1 (de) 2012-07-25
EP2267452A1 (de) 2010-12-29
MXPA03011455A (es) 2004-04-05
EP1402015A2 (de) 2004-03-31
ES2391623T3 (es) 2012-11-28
CN1524123A (zh) 2004-08-25
PL215170B1 (pl) 2013-10-31
EP1402041B1 (de) 2009-10-07
KR20060027871A (ko) 2006-03-28
WO2003000877A3 (en) 2003-10-30
US8426167B2 (en) 2013-04-23
JP4262594B2 (ja) 2009-05-13
JP2007322436A (ja) 2007-12-13
KR100611545B1 (ko) 2006-08-10
JP2004535195A (ja) 2004-11-25
HK1068918A1 (en) 2005-05-06
PL218245B1 (pl) 2014-10-31
AU2002325265B2 (en) 2006-10-19
WO2003000878A2 (en) 2003-01-03
CA2449747C (en) 2010-04-13

Similar Documents

Publication Publication Date Title
ATE445016T1 (de) Verwendung von fkbp-chaperons als expressionswerkzeug
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
NO991078L (no) HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV
DE60037450D1 (de) Funf-helix protein
ATE315667T1 (de) Amplifizierung und detektion von hiv-1 und/oder hiv-2
EP1878742A3 (de) HIV-Peptide, -Antigene, -Impfstoffzusammensetzungen und -Immunoassay sowie Verfahren zur Erkennung von durch HIV induzierten Antikörpern
ATE364621T1 (de) Hiv-peptide
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
PT1159278E (pt) Inibidores de aspartil-protease
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2003052122A3 (en) Gp41 inhibitor
JP2002508338A5 (de)
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
AR015659A1 (es) Un procedimiento para la deteccion de anticuerpos contra el hiv y antigenos usados en el mismo.
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
TH87273A (th) วัคซีน
DE69928275D1 (de) Verfahren zur bestimmung der prognose für hiv-infizierte individuen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1402041

Country of ref document: EP